Summer 2026 Policy Priorities
As Congress heads into the August recess and attention increasingly turns toward the 2026 midterm elections, several major funding and regulatory issues remain front and center for academic cancer centers.
Last month, AACI submitted institutional comments in response to the White House Office of Management and Budget (OMB) proposed rule, Regulation for Federal Financial Assistance, to express concerns about provisions that could impact merit review and grant delivery. The Senate recently passed a continuing resolution, which would fund the government through December 11 and delay implementation of the proposal. While this is an encouraging development, differences with the House-passed measure are awaiting resolution.
AACI is closely monitoring the 340B Drug Pricing Program and how potential updates may impact cancer centers. Centers for Medicare & Medicaid Services proposed significant changes to 340B reimbursement through the CY 2027 Hospital Outpatient Prospective Payment System rule, while the Health Resources and Services Administration is proceeding with a revised 340B rebate pilot. Meanwhile, a bipartisan group of senators recently introduced the SUSTAIN 340B Act, reflecting continued congressional interest in the future of the program.
While lawmakers work toward final funding levels for the National Institutes of Health (NIH) and National Cancer Institute (NCI), AACI continues to advocate for robust, sustained investment in biomedical research and amplify the collective voice of academic cancer centers in Washington.
|